News from polaris group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NYSE:PII)

Dec 18, 2014, 13:30 ET
Polaris Group

Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma

 Polaris Group announced today that its lead product candidate ADI-PEG 20 (pegylated arginine deiminase) has received orphan drug designation...

Dec 10, 2014, 13:30 ET
Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Advanced Hepatocellular Carcinoma

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with sorafenib, a current...

Dec 03, 2014, 13:30 ET
Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer

 Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with...

Dec 02, 2014, 07:15 ET

Polaris Transportation Announces New VP for U.S. Operations

MISSISSAUGA, ON, Dec. 2, 2014 /PRNewswire/ - The management at Polaris Transportation Group is excited to announce the appointment of David Bush as...

Dec 01, 2014, 13:30 ET
Polaris Group

Data Published by Researchers from Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity through Previously Unidentified Mechanism

 Polaris Group announced today that data from a recent publication in the Proceedings of the National Academy of Sciences of the USA (PNAS)...

Nov 20, 2014, 13:30 ET
Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin...

Nov 18, 2014, 13:30 ET
Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Doxorubicin in HER2 Negative Breast Cancer

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with doxorubicin for the...

Apr 29, 2014, 15:15 ET
Apr 02, 2014, 17:00 ET

Shaw T. Chen, M.D., Ph.D. joins Polaris

 Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) as...

Jan 27, 2014, 10:30 ET

Polaris Group's ADI-PEG 20 is a Radiosensitizer of Pancreatic Cancer

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, acts as a radiosensitizer of pancreatic...

Dec 02, 2013, 10:30 ET

Polaris Group Files New IND for ADI-PEG 20 in Leukemia

 Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...

Nov 06, 2013, 15:00 ET
Polaris Group.  (PRNewsFoto/Polaris Group)

Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia

 Polaris Group announced today that the first patient has been dosed in its Phase 2 trial of ADI-PEG 20, arginine deiminase formulated...

Oct 28, 2013, 07:00 ET

Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with...

Oct 25, 2013, 17:55 ET
Polaris is a Canadian LTL carrier that provides scheduled, daily service between its Southern Ontario base and all points in the U.S. and Western Canada. The recipient of many awards for its dedication to service excellence, it is particularly proud of this recognition of its commitment to environmental leadership.  (PRNewsFoto/Polaris Transportation Group)

Polaris Transport Receives US EPA 2013 SmartWay Excellence Award

TORONTO, Oct. 25, 2013 /PRNewswire/ - Polaris Transport was honored with a SmartWay® Excellence Award from the U.S. Environmental Protection...

Oct 22, 2013, 10:00 ET

Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer

 Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...

Apr 17, 2013, 10:00 ET
Jun 12, 2012, 09:00 ET
Feb 29, 2012, 10:29 ET

Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma

 Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer...

Jan 10, 2012, 09:00 ET

Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Combination with Docetaxel in Advanced Solid Tumors with Emphasis on Prostate Cancer

SAN DIEGO, Jan. 10, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1...

Jul 28, 2011, 08:00 ET

Polaris Group Doses First Patient in Pivotal Phase 3 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 for the Treatment of Hepatocellular Carcinoma

Polaris Group (Polaris) today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer...